Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
about
Gemcitabine for unresectable, locally advanced or metastatic bladder cancerSaudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladderIncreased risk of high-grade hemorrhage in cancer patients treated with gemcitabine: a meta-analysis of 20 randomized controlled trialsRandomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract.An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerAdvanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapySaudi oncology society and Saudi urology association combined clinical management guidelines for urothelial urinary bladder cancer.Saudi Oncology Society clinical management guidelines for urinary bladder cancer.Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy.Current therapeutic strategies for invasive and metastatic bladder cancer.A pure microcytic bladder carcinoma synchronous to prostatic adenocarcinoma.Inhibiting bladder tumor growth with a cell penetrating R11 peptide derived from the p53 C-terminus.Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)Urothelial carcinoma management in elderly or unfit patients.Serum C-reactive protein level is a significant prognostic indicator in patients with advanced urothelial cancer treated with gemcitabine-cisplatin or carboplatin - preliminary results.Current chemotherapeutic strategies against bladder cancer.Management of advanced bladder cancer in patients with impaired renal function.Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.Chemotherapy for bladder cancer in patients with impaired renal function.Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response.Current treatment of metastatic bladder cancer and future directions.Current management of muscle-invasive bladder cancer.Neoadjuvant chemotherapy for invasive bladder cancer.The role of systemic chemotherapy in management of upper tract urothelial cancer.VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients inIn vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors.Current status of systemic chemotherapy for octogenarians with advanced urothelial cancer in Japan: a Japanese multi-institutional study (CURE study).Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy.Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host.[Systemic therapy of metastatic bladder cancer.]The renal safety and efficacy of combined gemcitabine plus cisplatin and gemcitabine plus carboplatin chemotherapy in Chinese patients with a solitary kidney after nephroureterectomy.Atezolizumab in urothelial bladder carcinoma.Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?Maximizing outcomes in genitourinary cancers across the treatment continuum.Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium.Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder 2017.Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P2860
Q24235162-172EF0C3-4486-4076-AF98-687421D162A6Q26747775-66FD6D97-B80E-420D-92BF-6511529EF05AQ28533753-D4E40B2F-4041-4D71-94D2-AE3F2E9097B5Q33398722-4C8022C1-3FD8-4B9B-BE73-FB1CC8E8F285Q33405638-24C940F2-FA32-4DAA-94AE-48B3D4941A0CQ33412123-B73CAB14-79B2-4A67-AABA-5976F81BC65CQ33417019-A266EBE3-EC8F-447B-B6F5-61A6F3AFB34CQ34437299-70E3959F-01F0-406A-9660-8D52D680C81FQ34997367-8DCB360F-483B-4D67-811B-54940C6F47B3Q35076309-C3013284-97BF-4F58-BCF9-EFC7DD05D870Q35128721-9C809E94-C64A-4308-969B-22D035667DE9Q35526843-7901C5A4-24C5-49C9-B4C0-4DE3D9DE5463Q36545877-318398D7-F4C1-4D64-A627-73751EC37014Q36627206-6DBBFFC6-5D8A-4F0A-85B8-53FEFD637954Q37030514-2BE6DFD9-FA9F-4F14-A394-F015655517D2Q37579125-780A17CD-0F43-4C0B-90C2-CADEF211F48EQ37888549-237E4027-8867-4D13-A3DD-0AD404BFC842Q37894683-ED63814F-1F8D-405F-87C1-22E97EDDF3F0Q37896172-A81FB3CF-05A2-4B58-9CBD-53075E0A163DQ37959263-3C4D69E7-3CBD-4775-B357-3D06E811A9C4Q37959798-3976028D-B042-4AEB-93A5-23D064ED1A84Q37960909-14ACD062-B065-459C-A856-0F60BD13C732Q37962658-21AA41B1-B05C-4FC1-9716-A15125782BFDQ37982318-855FF701-1990-473F-87C1-6D52FB32F8D2Q38076327-A6F8A367-2F8F-473E-9FA5-953D304D7135Q39015065-A9D0DA8B-1497-4ACF-895E-00680E3409ACQ39136346-D73E2AAF-11FC-4757-8CD6-F88C747BD252Q39651302-6192EDDF-CCDE-4703-AB35-7A72667096F1Q39766258-9D950DC3-6B19-488B-82D1-FA29FF464CF8Q43879300-EEBA067F-AA7E-450B-87A8-BDEB70B7F431Q44419809-DD021D4C-F834-4C22-A725-D86951012EA0Q47367089-ECDB2CAA-31A3-4C3E-B50C-F8673E293C53Q47841004-2FA8157B-C21F-44F1-9BB8-34C5166D14F3Q50240602-47974589-F53B-42AD-AD5A-9D8C62FED803Q50246373-6903764F-86F2-41BE-8F11-AB7AF25945FFQ50355469-218D7999-A7D5-4CD6-B72D-6620CF1C6888Q53236575-974D63CD-AEDA-4779-BF12-5CA2C7A1899AQ53250202-3F101E0D-3AB1-4DBB-88A0-07BA7A119AE8Q55013973-3E25753B-418A-4029-AC67-B3EF273C1E81Q57278901-97E20D0C-5CB6-4D99-8E41-D27B618A7161
P2860
Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Randomized phase II/III trial ...... -results of EORTC study 30986.
@en
Randomized phase II/III trial ...... -results of EORTC study 30986.
@nl
type
label
Randomized phase II/III trial ...... -results of EORTC study 30986.
@en
Randomized phase II/III trial ...... -results of EORTC study 30986.
@nl
prefLabel
Randomized phase II/III trial ...... -results of EORTC study 30986.
@en
Randomized phase II/III trial ...... -results of EORTC study 30986.
@nl
P2093
P2860
P921
P356
P1476
Randomized phase II/III trial ...... --results of EORTC study 30986
@en
P2093
Graham Mead
Iwona Skoneczna
J Martijn Kerst
Joaquim Bellmunt
Maria De Santis
Pablo Maroto
Richard Sylvester
Ronald de Wit
Sandrine Marreaud
P2860
P304
P356
10.1200/JCO.2008.21.4924
P407
P50
P577
2009-09-28T00:00:00Z